Intended for healthcare professionals

Letters FGM Enhanced Data Collection

Mandatory submission of patient identifiable information to third parties: FGM now, what next?

BMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h5146 (Published 30 September 2015) Cite this as: BMJ 2015;351:h5146
  1. Susan Bewley, professor of complex obstetrics1,
  2. Brenda Kelly, consultant obstetrician and clinical lead for the Oxford Rose Clinic2,
  3. Katrina Darke, general practitioner and clinical lead for the Bristol Community Rose Clinic3,
  4. Katrina Erskine, consultant obstetrician and gynaecologist and associate medical director4,
  5. Clare Gerada, general practitioner5,
  6. Patricia Lohr, medical director6,
  7. Paquita de Zulueta, honorary senior clinical lecturer7
  1. 1Women’s Health Academic Centre, St Thomas’ Hospital, London SE1 7EH, UK
  2. 2Oxford University Hospitals NHS Trust, Oxford, UK
  3. 3Lawrence Hill Health Centre, Bristol, UK
  4. 4Homerton University Hospital, London
  5. 5Hurley Clinic, London
  6. 6British Pregnancy Advisory Service, London
  7. 7Department of Public Health and Primary Care, Imperial College London, London
  1. susan.bewley{at}kcl.ac.uk

The government has done much to tackle female genital mutilation (FGM),1 2 3 but the planned rollout of FGM Enhanced Data Collection across the NHS in October 2015 is ill considered. All healthcare professionals will be legally obliged to submit highly sensitive, patient identifiable information on every woman with FGM attending the NHS for whatever reason. A woeful consultation preceded the ministerial direction, which also says patient consent is not needed. While stating that confidential data will not be released to third parties (such as police, Crown Prosecution Service), the reassurance is inadequate and not future proofed.4 5 6 The legal responsibility for communicating that this information will be collected, where it will be sent, and what may happen to it is devolved to frontline clinicians.7 8 The push to implement an electronic infrastructure and opt-out that is not fit for purpose will bring already compromised patient confidence closer to breaking point.9 10 The initiative has no evidence of benefit, wastes precious clinical time, and will profoundly damage trust in health professionals who will either collude or ignore the imperative.

Correspondence with the minister of public health and civil servants remains unanswered. The Department of Health seems wilfully unaware of the wider ramifications of breaching confidentiality and the impact on the human and healthcare rights of already disadvantaged women and their families. Rather than tackling FGM, this measure is likely to be counterproductive and hinder eradication strategies.

Confidentiality is not absolute, but it underpins the doctor-patient relationship.11 Without reiterating countervailing ethical and professional duties, the GMC recently emailed all doctors about their obligation to breach confidentiality if the government has made a law compelling them to do so.12 But such law is unnecessary and misguided. The government still has time to reflect and pull back from a policy that wrecks the basic medical promise of confidentiality.

Notes

Cite this as: BMJ 2015;351:h5146

Footnotes

  • Competing interests: Set up or run FGM clinics since 1996 (SB, KD, KE, BK); publications about FGM (SB, KE, KD, BK, PdeZ); expert advice to UK’s first FGM trial 2014 (SB). Other authors: none declared.

  • Full response at: www.bmj.com/content/350/bmj.h1467/rr.

References